In early February 2023, I submitted an application to the Interventions Testing Program (ITP) at the NIH. The scientists at the ITP are constantly on the lookout for ideas on interventions to test for their effects on life span in mice. Currently, the best performing intervention that has been tested at the ITP is rapamycin. However the continuous daily administration of rapamycin used in the studies done so far by the ITP has some potential downsides that might result in side effects and less than optimal benefits. The idea I have, which is the basis for the application I wrote, is to test rapamycin at an intermittent dosing schedule interval, designed to minimize the side effects while retaining much of the beneficial effects of rapamycin on longevity in mice. The intermittent dosing schedule is designed to reach an optimal balance between benefits and side effects. The main gist of the proposal I sent to the ITP is below.
Share this post
Rapamycin proposal to the ITP
Share this post
In early February 2023, I submitted an application to the Interventions Testing Program (ITP) at the NIH. The scientists at the ITP are constantly on the lookout for ideas on interventions to test for their effects on life span in mice. Currently, the best performing intervention that has been tested at the ITP is rapamycin. However the continuous daily administration of rapamycin used in the studies done so far by the ITP has some potential downsides that might result in side effects and less than optimal benefits. The idea I have, which is the basis for the application I wrote, is to test rapamycin at an intermittent dosing schedule interval, designed to minimize the side effects while retaining much of the beneficial effects of rapamycin on longevity in mice. The intermittent dosing schedule is designed to reach an optimal balance between benefits and side effects. The main gist of the proposal I sent to the ITP is below.